What insurance policy changes affect code H81.10?

There are 5 tracked policy changes affecting code H81.10, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code H81.10?

Payers that have issued tracked updates for code H81.10 include: Aetna.

How do I get notified when code H81.10 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code H81.10. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code H81.10?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

PAYER POLICY CHANGES

H81.10 Insurance Policy Changes

ICD-10 H81.10 is officially defined as "Benign paroxysmal vertigo, unspecified ear." code H81.10 is referenced in 5 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code H81.10 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 1, 2026Medium impact
Endolymphatic Hydrops (Meniere's Disease) Tests (CPB 0571, reviewed 2026-09-01)
Aetna considers dehydration testing with glycerol, urea, or other osmotic diuretics medically necessary to verify suspected endolymphatic hydrops (Meniere's disease) only in members with atypical presentations of the disease, and considers it experimental, investigational, or unproven for other indications. Aetna considers the following experimental, investigational, or unproven: endolymphatic sac immunohistochemistry of aquaporin-2, V2R, NKCC2 and TRPV4; genetic testing of KCNE1, KCNE3, SIK1, SLC8A1 and SLC26A4 for this diagnosis; intravenous gadolinium inner ear MRI; multi-frequency tympanometry; testing for antibodies against inner ear antigens; vestibular evoked myogenic potential (VEMP) testing for diagnosis and for monitoring disease progression; and the video head impulse test. The policy lists CPT codes 81406, 92517, 92518, 92519, 92550, 92567 and 92584 and HCPCS code A9579 as not covered for the indications listed, and ICD-10 codes for Meniere's disease, related vertigo, labyrinthitis, gait abnormalities and dizziness are covered if selection criteria are met.
Aetna · Identified Aug 19, 2026Medium impact
Vestibular Autorotation Test (VAT) (CPB 0467, reviewed 2026-08-03)
Aetna considers the vestibular autorotation test (VAT) experimental, investigational, or unproven for diagnosing vestibular disorders, vestibular migraine, or any other indication. Its sensitivity, specificity, reproducibility, and clinical utility have not been demonstrated. There are no specific codes for VAT, and the related CPT vestibular function test codes are 92541 through 92548.
Aetna · Identified Aug 14, 2026Medium impact
Endolymphatic Hydrops (Meniere's Disease) Tests (CPB 0571, reviewed 2025-12-02)
Aetna considers dehydration testing with glycerol, urea, or other osmotic diuretics medically necessary to verify suspected endolymphatic hydrops (Meniere's disease) only in members with atypical presentations, and considers it experimental, investigational, or unproven for other indications. The policy also lists as experimental, investigational, or unproven: endolymphatic sac immunohistochemistry, genetic testing of KCNE1, KCNE3, SIK1, SLC8A1, and SLC26A4 for diagnosis, intravenous gadolinium inner ear MRI, multi-frequency tympanometry, testing for antibodies against inner ear antigens, VEMP for diagnosis and for monitoring disease progression, and the video head impulse test.
Aetna · Identified Aug 14, 2026Medium impact
Chronic Vertigo (CPB 0238, reviewed 2026-04-23)
Aetna considers the Epley and Semont maneuvers medically necessary for benign paroxysmal positional vertigo only when a positive Hallpike test confirms the diagnosis and the member has had symptoms for at least 4 months, and considers them experimental for members with central nervous system disorders such as temporal lobe epilepsy, multiple sclerosis, cerebrovascular disease, or cerebellar lesions. Vestibular rehabilitation is medically necessary for chronic vertigo or persistent postural-perceptual dizziness when symptoms have lasted more than 6 months, a vestibular disorder is confirmed or ablative vestibular surgery was performed, and medical management has failed. Dynamic posturography, the Meniett device, the DizzyFix, the GyroStim machine, the Biodex BioSway, the BTrackS system, and posterior semicircular canal occlusion are listed as experimental, investigational, or unproven.
Aetna · Identified Aug 14, 2026Medium impact
Electrocochleogram and Perilymphatic Pressure Measurement (CPB 0564, reviewed 2026-07-30)
Aetna covers electrocochleography (CPT 92584) when it is used to evaluate episodic dizziness (vertigo or imbalance) or tinnitus to rule out endolymphatic hydrops (Meniere's disease) and perilymphatic fistula, or when it is performed with auditory brainstem response testing for profound hearing loss, defined as a pure tone average of 90 dB HL or greater at 500, 1,000, 2,000 and 4,000 Hz. Electrocochleography is experimental, investigational or unproven for routine hearing screening, for improving pre-implantation counseling for cochlear implant recipients, for intra-operative evaluation of cochlear trauma during cochlear implantation, and for superior semicircular canal dehiscence repair and canal resurfacing. Measurement of perilymphatic pressure is experimental, investigational or unproven for managing Meniere's disease or idiopathic sudden sensorineural hearing loss.

Watch H81.10

Get one email when a payer policy names H81.10, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Endolymphatic Hydrops (Meniere's Disease) Tests (CPB 0571, reviewed 2026-09-01)

Vestibular Autorotation Test (VAT) (CPB 0467, reviewed 2026-08-03)

Endolymphatic Hydrops (Meniere's Disease) Tests (CPB 0571, reviewed 2025-12-02)

Chronic Vertigo (CPB 0238, reviewed 2026-04-23)

Electrocochleogram and Perilymphatic Pressure Measurement (CPB 0564, reviewed 2026-07-30)

What insurance policy changes affect code H81.10?

Which payers have updated policy for code H81.10?

How do I get notified when code H81.10 policy changes?

Why do payers change policies for code H81.10?